Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

PROTECT Prevent and Bypass - a Vision to Protect Blood Cells from Adverse Immune Responses

Coordinator
Universitatsmedizin Greifswald Korperschaft Des Offentlichen Rechts, Germany
Runs
1 October 2026 to 30 September 2031
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101264330

What the project is doing

In the project's own words, from its summary on CORDIS.

PROTECT: Advancing Blood Cell Protection from Immune Attack This ERC Advanced Grant project, PROTECT, aims to overcome challenges in preventing adverse immune responses against blood cells induced by essential medical interventions: vaccination, transfusion, and thrombosis prophylaxis. Despite their life-saving potential, these therapies can trigger rare but severe complications due to antibody-mediated immune activation.

PROTECT addresses this through two interconnected challenges: PREVENT, focusing on adenovirus vector vaccine safety by elucidating the mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis (VITT); and BYPASS, aiming to enable safe transfusions for immunized patients by enzymatically removing antigenic proteins from donor blood cells. PREVENT will investigate the specific adenoviral components triggering the anti-PF4 response, utilizing advanced proteomics, genetics, and humanized mouse models.

BYPASS will leverage innovative enzyme engineering and targeted protein degradation to modify blood products in situ, offering a paradigm shift in transfusion medicine. By integrating mechanistic insights with translational approaches, PROTECT strives to develop preventative and corrective strategies, ultimately preserving public trust in life-saving medical practices and establishing a unique human model system for alloimmunization research.

This ambitious program promises high-gain potential with lasting impact on patient care and blood product safety.

Topics

Who is involved

OrganisationCityCountryRole
Universitatsmedizin Greifswald Korperschaft Des Offentlichen RechtsGreifswaldGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI